

Pharmacy Drug Policy Checklist

POLICY NAME Rezdiffra (resmetirom) POLICY # 3374P

Criteria

| Coverage Criteria | |
|---|---|
| | 1.1 Diagnosis of noncirrhotic nonalcoholic steatohepatitis (liver disease) (NASH/MASH) Diagnosis confirmed by one of the following: liver biopsy, elastography (MRE or VCTE), magnetic resonance imaging (MRI), serum or imaging biomarker (Fibroscan, NFS, ELF) |
| | 1.2 Evidence of moderate to advanced liver fibrosis as evidenced by stages F2 to F3 fibrosis |
| | 1.3 Age 18 years or older |
| | 1.4 Prescribed by or in consultation with a hepatologist (liver doctor) |
| | 1.5 Evidence of additional conditions such as prediabetes or type 2 diabetes, obesity, hypertension, etc |
| | 1.6 Rezdiffra will be used in in addition to diet and exercise |
| Exclusion Criteria – Any of the following prevents coverage | |
| | 2.1 Evidence of decompensated cirrhosis |
| | 2.2 F1 or F4 fibrosis |
| | 2.3 Evidence of significant alcohol consumption (defined as ≥20g/day for females or ≥30g/day for males) |